Press Releases

Date Title
February 23, 2021 Progenity Announces $25 Million Private Placement
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it has entered into a definitive securities purchase
February 17, 2021 Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS)
February 12, 2021 SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
Progenity applauds focus on preeclampsia biomarkers as it prepares for the launch of the Preecludia™ test SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular
February 10, 2021 Progenity to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of
January 20, 2021 Progenity Reaches Two Million Test Milestone
The company celebrates its ten-year anniversary and looks toward future innovations SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, has
January 13, 2021 Progenity Provides Financial Guidance for Full-year 2021
Total 2021 revenue expected to grow by up to 30% 1 , reaching a range of $130 to $145 million Core molecular testing 2 volume expected to grow by up to 16% SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of
January 5, 2021 Progenity to Present at the 2021 ICR Conference
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced its participation in the 2021 ICR Conference.
December 17, 2020 Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity , Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products in women’s health, today announced that it is expanding the availability of COVID-19 RT-PCR
December 8, 2020 Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser’s Option to Purchase Additional Notes
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the closing of its offering of $85,525,000 aggregate principal amount of
December 8, 2020 Progenity Announces Closing of Public Offering of Common Stock
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the closing of its previously announced underwritten public
Displaying 31 - 40 of 86